Table 2.
Individual oncological data (n=6)
| Patient | Interval between HIFU and EBRT, months | PSA nadir after EBRT | Time to obtain PSA nadir, months | PSA value at the end of follow-up | Follow-up after EBRT, months | Biochemical failure (nadir + 2 ng/mL) | Salvage therapy |
|---|---|---|---|---|---|---|---|
| #2 | 9 | 2.4 | 12 | 0.01 | 54 | Yes | ADT |
| #3 | 20 | 0.34 | 18 | 0.36 | 24 | No | |
| #4 | 12 | 0.03 | 18 | 0.03 | 38 | No | |
| #5 | 11 | 0.64 | 24 | 0.64 | 37 | No | |
| #6 | 10 | 0.07 | 24 | 0.07 | 25 | No | |
| #7 | 9 | 0.23 | 36 | 0.23 | 36 | No |
HIFU: high-intensity focused ultrasound; PSA: prostate-specific antigen; EBRT: external beam radiotherapy; ADT, Androgen deprivation therapy.